Igenica Biotherapeutics, Inc.

Igenica Biotherapeutics, Inc. specializes in biotherapeutics, focusing on developing innovative treatments for various diseases using advanced biological techniques. Founded in 2009 in Burlingame, US, Igenica Biotherapeutics, Inc. is dedicated to biotherapeutic innovations.

The company has conducted 10 deals, with its most recent funding round of USD 1. 230 mn completed on May 23, 2017, which represents the total amount raised. The founder's history is not specifically detailed in available information. Igenica Biotherapeutics, Inc.

focuses on developing and providing biotherapeutic solutions. Their core offerings include targeted drug discovery and development aimed at addressing unmet medical needs. The company’s expertise spans various therapeutic areas, positioning them to cater to the evolving landscape of biological treatments. Revenue generation for Igenica Biotherapeutics is primarily driven by its biotherapeutic development services, which operate on a project basis.

Clients engage in collaborations by submitting research and development requests that receive customized solutions tailored to their therapeutic objectives. Specific financial details regarding revenue are not publicly outlined. Igenica Biotherapeutics plans to expand its research and development initiatives with new product offerings focused on cutting-edge biotherapeutics in the coming years. The company is targeting increased market presence in North America and Europe by 2025.

The funding received in May 2017 will be utilized to enhance R&D efforts, supporting the launch of innovative treatment options.